{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:25:05Z","timestamp":1787027105413,"version":"build-2736575974"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Managed Entry Agreements (MEAs) are pivotal for enabling access to innovative pharmaceuticals while mitigating financial risk and addressing evidence uncertainty. Despite conceptual acceptance, the essential requirements for their design and implementation are poorly documented, posing a challenge for evolving health systems. This study aimed to systematically review and map global evidence published in the literature on the existence and characterization of countries\u2019 MEA policies, focusing on the core system-level components, governance, and operational frameworks for successful implementation, and their associated development and implementation challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted following PRISMA guidelines. MEDLINE and EMBASE were searched from inception to March 2025. Studies discussing governance, frameworks, legislation, or implementation of pharmaceutical MEAs were included. Data were extracted and synthesized narratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 96 included studies, most focused on European (43%) and North American (28%) systems, with a significant evidence gap for the Middle East and low-income countries. While situational analysis was the most common theme (63%), the literature predominantly catalogued barriers rather than providing operational solutions. Key barriers were inefficient regulatory frameworks (identified in 42% of studies), data infrastructure limitations (41%), and high administrative burden (38%). Stakeholder analysis highlighted underrepresentation of academia and civil society. A minority of studies (15%) focused on Advanced Therapy Medicinal Products (ATMPs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review identifies a critical \u201chow-to\u201d gap in the MEA literature. While the value of MEAs is acknowledged, there is a stark deficit of actionable, system-level guidance on the regulatory, governance, and operational prerequisites for implementation. For health systems seeking to adopt MEAs, future efforts must shift from describing barriers to developing concrete implementation toolkits, legislative roadmaps, and fit-for-purpose payment models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1803870","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:24:19Z","timestamp":1776662659000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mapping the landscape of managed entry agreements: a systematic review of global frameworks, system-level components, and implementation challenges"],"prefix":"10.3389","volume":"17","author":[{"given":"Hussain Abdulrahman","family":"Al-Omar","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma Abdulaziz","family":"Almuhsin","sequence":"additional","affiliation":[{"name":"General Directorate of Research and Studies, Deputyship of Planning and Institutional Excellence, Ministry of Health","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lolwa Hamad","family":"Almudaiyan","sequence":"additional","affiliation":[{"name":"Center for Health Technology Assessment, Ministry of Health","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal Hassan","family":"Al-Najjar","sequence":"additional","affiliation":[{"name":"Center for Health Technology Assessment, Ministry of Health","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila Carolina","family":"Abu Esba","sequence":"additional","affiliation":[{"name":"King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Ministry of National Guard","place":["Riyadh, Saudi Arabia"]},{"name":"King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Almodaimegh","sequence":"additional","affiliation":[{"name":"King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Centre","place":["Riyadh, Saudi Arabia"]},{"name":"Ministry of National Guard - Health Affairs","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehan","family":"Alamre","sequence":"additional","affiliation":[{"name":"Logistics and Contracts Management, King Abdulaziz Medical City, Ministry of National Guard- Health Affairs, Ministry of National Guard","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuela Cheriece","family":"Yousef","sequence":"additional","affiliation":[{"name":"Imam Abdulrahman Bin Faisal Hospital, Ministry of National Guard, Health Affairs","place":["Dammam, Saudi Arabia"]},{"name":"King Saud Bin Abdulaziz University for Health Sciences","place":["Al Ahsa, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Centre","place":["Al Ahsa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor Ahmed","family":"Khan","sequence":"additional","affiliation":[{"name":"King Abdulaziz Medical City, Ministry of National Guards Health Affairs","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"AlYahya","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Service, Prince Sultan Military Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa S.","family":"Altawil","sequence":"additional","affiliation":[{"name":"Corporate Pharmacy Service, King Saud University Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdualmajeed Saad","family":"Binjumayah","sequence":"additional","affiliation":[{"name":"Tawuniya Insurance Company","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Awwadh","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Tawuniya Insurance Company","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan Tawfiq","family":"AlShurbaji","sequence":"additional","affiliation":[{"name":"University of York","place":["York, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Maraiki","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Esp\u00edn","sequence":"additional","affiliation":[{"name":"Andalusian School of Public Health, Escuela Andaluza de Salud P\u00fablica (EASP)","place":["Granada, Spain"]},{"name":"CIBER en Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), CIBER of Epidemiology and Public Health (CIBERESP), Instituto de Investigaci\u00f3n Biosanitaria ibs.GRANADA","place":["Granada, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Tarricone","sequence":"additional","affiliation":[{"name":"Department of Social and Political Sciences, Bocconi University","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos","family":"Kanavos","sequence":"additional","affiliation":[{"name":"Department of Health Policy, London School of Economics and Political Science, LSE Health-Medical Technology Research Group","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1472-6963-10-153","article-title":"Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers","volume":"10","author":"Adamski","year":"2010","journal-title":"BMC Health Serv. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jsps.2020.04.006","article-title":"Pharmaceutical companies' views on a health technology assessment (HTA) entity in Saudi Arabia","volume":"28","author":"Al-Omar","year":"","journal-title":"Saudi Pharm. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/14737167.2019.1610398","article-title":"What local experts expect from a health technology assessment (HTA) entity in Saudi Arabia: workshop conclusions","volume":"20","author":"Al-Omar","year":"","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/14737167.2020.1792295","article-title":"Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach","volume":"21","author":"Al-Omar","year":"2021","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1080\/13696998.2025.2577514","article-title":"Toward an ethical future for orphan drugs: balancing access, affordability, and innovation","volume":"28","author":"Alum","year":"2025","journal-title":"J. Med. Econ."},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fphar.2011.00057","article-title":"Valorising and creating access to innovative medicines in the european union","volume":"2","author":"Annemans","year":"2011","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/21678707.2021.1913121","article-title":"The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways","volume":"9","author":"Bang","year":"2021","journal-title":"Expert Opin. Orphan Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/hec.1603","article-title":"The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry","volume":"20","author":"Barros","year":"2011","journal-title":"Health Econ."},{"key":"B9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1163\/15718093-bja10121","article-title":"What are the changes in 2023 for access to advanced therapy medicinal products (ATMPs) in France?","volume":"31","author":"Bartos","year":"2024","journal-title":"Eur. J. Health Law"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13485","DOI":"10.3389\/ti.2024.13485","article-title":"ESOT roadmap for advanced therapy medicinal products in transplantation: navigating regulatory challenges to enhance access and care","volume":"37","author":"Berishvili","year":"2024","journal-title":"Transpl. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/1468-0009.12703","article-title":"Experiences and interest in value-based payment arrangements for medical products among medicaid agencies: an exploratory analysis","volume":"102","author":"Bhuiyan","year":"2024","journal-title":"Milbank Q."},{"key":"B12","volume-title":"Saudi Arabia pharmaceuticals report includes 10-year forecasts to 2033- Q3 2024","year":"2024"},{"key":"B13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fphar.2018.00280","article-title":"Managed entry agreements for pharmaceuticals in the context of adaptive pathways in Europe","volume":"9","author":"Bouvy","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jval.2017.07.009","article-title":"Payer and pharmaceutical manufacturer considerations for outcomes-based agreements in the United States","volume":"21","author":"Brown","year":"2018","journal-title":"Value Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2146\/ajhp160398","article-title":"Emerging roles for pharmacists in performance-based risk-sharing arrangements","volume":"74","author":"Calabrese","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"104048","DOI":"10.1016\/j.drudis.2024.104048","article-title":"Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity","volume":"29","author":"Callenbach","year":"2024","journal-title":"Drug Discov. Today"},{"key":"B17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.18553\/jmcp.2009.15.8.683","article-title":"Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals","volume":"15","author":"Carlson","year":"2009","journal-title":"J. Manag. Care Pharm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","article-title":"Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers","volume":"96","author":"Carlson","year":"2010","journal-title":"Health Policy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40258-014-0093-x","article-title":"Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers","volume":"12","author":"Carlson","year":"2014","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s40273-017-0535-z","article-title":"Performance-based risk-sharing arrangements: an updated international review","volume":"35","author":"Carlson","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jtct.2025.09.044","article-title":"Under the hood: evidence-based review of allogeneic chimeric antigen receptor T cells for hematologic malignancies","volume":"32","author":"Cheema","year":"2025","journal-title":"Transpl. Cell Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00520-022-07486-5","article-title":"Building infrastructure for outcomes-based agreements in Canada: can administrative health data be used to support an outcomes-based agreement in oncology?","volume":"31","author":"Cheung","year":"2022","journal-title":"Support Care Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jval.2016.03.2003","article-title":"A comprehensive algorithm for approval of health technologies with, without, or only in research: the key principles for informing coverage decisions","volume":"19","author":"Claxton","year":"2016","journal-title":"Value Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13696998.2016.1215991","article-title":"Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer","volume":"20","author":"Clopes","year":"2017","journal-title":"J. Med. Econ."},{"key":"B25","volume-title":"CASP checklist for qualitative studies","year":"2020"},{"key":"B26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2019.12.008","article-title":"Managed entry agreements: policy analysis from the european perspective","volume":"23","author":"Dabbous","year":"2020","journal-title":"Value Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-024-03041-z","article-title":"Real-world evidence for coverage determination of treatments for rare diseases","volume":"19","author":"Dayer","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10198-015-0683-z","article-title":"When do performance-based risk-sharing arrangements make sense?","volume":"16","author":"Drummond","year":"2015","journal-title":"Eur. J. Health Econ."},{"key":"B29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.18553\/jmcp.2017.16326","article-title":"The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey","volume":"24","author":"Duhig","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B30","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.healthpol.2018.02.008","article-title":"Innovative pharmaceutical pricing agreements in five European markets: a survey of stakeholder attitudes and experience","volume":"122","author":"Dunlop","year":"2018","journal-title":"Health Policy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40273-013-0038-5","article-title":"Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing","volume":"31","author":"Eckermann","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/cpt.2471","article-title":"Precision reimbursement for precision medicine: using real-world evidence to evolve from trial-and-project to track-and-pay to learn-and-predict","volume":"111","author":"Eichler","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.3982\/ECTA8772","article-title":"Mechanism design with renegotiation and costly messages","volume":"80","author":"Evans","year":"2012","journal-title":"Econometrica"},{"key":"B34","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/cpt.508","article-title":"Pricing and reimbursement experiences and insights in the european union and the United States: lessons learned to approach adaptive payer pathways","volume":"100","author":"Faulkner","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.socscimed.2014.11.003","article-title":"Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden","volume":"124","author":"Ferrario","year":"2015","journal-title":"Soc. Sci. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hec.4112","article-title":"The impact of managed entry agreements on pharmaceutical prices","volume":"29","author":"Gamba","year":"2020","journal-title":"Health Econ."},{"key":"B37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1017\/S0266462311000079","article-title":"Risk sharing agreements: what lessons from Italy?","volume":"27","author":"Garattini","year":"2011","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10198-014-0585-5","article-title":"Italian risk-sharing agreements on drugs: are they worthwhile?","volume":"16","author":"Garattini","year":"2015","journal-title":"Eur. J. Health Econ."},{"key":"B39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","article-title":"Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force","volume":"16","author":"Garrison","year":"2013","journal-title":"Value Health"},{"key":"B40","first-page":"632","article-title":"Private sector risk-sharing agreements in the United States: trends, barriers, and prospects","volume":"21","author":"Garrison","year":"2015","journal-title":"Am. J. Manag. Care"},{"key":"B41","volume-title":"Saudi minister of health openning speech for global health exhibition","year":"2024"},{"key":"B42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/medlaw\/fwu005","article-title":"Niche markets and evidence assessment in transition: a critical review of proposed drug reforms","volume":"22","author":"Gibson","year":"2014","journal-title":"Med. Law Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.18553\/jmcp.2017.23.10.1042","article-title":"Performance-based risk-sharing arrangements: U.S. payer experience","volume":"23","author":"Goble","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2483613","DOI":"10.1080\/20565623.2025.2483613","article-title":"CAR-T cell therapies: patient access and affordability solutions","volume":"11","author":"Goncalves","year":"2025","journal-title":"Future Sci. OA"},{"key":"B45","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3332\/ecancer.2018.823","article-title":"Risk-sharing agreements, present and future","volume":"12","author":"Goncalves","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.18553\/jmcp.2019.19167","article-title":"Regulatory, policy, and operational considerations for outcomes-based risk-sharing agreements in the U.S. market: opportunities for reform","volume":"25","author":"Goodman","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40273-017-0562-9","article-title":"The HTA risk analysis chart: visualising the need for and potential value of managed entry agreements in health technology assessment","volume":"35","author":"Grimm","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1090721","DOI":"10.3389\/fmed.2023.1090721","article-title":"Barriers to treg therapy in Europe: from production to regulation","volume":"10","author":"Hennessy","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jval.2018.08.007","article-title":"Determining the comparative value of pharmaceutical risk-sharing policies in non-small cell lung cancer using real-world data","volume":"22","author":"Holleman","year":"2019","journal-title":"Value Health"},{"key":"B50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/healthcare12010119","article-title":"Stakeholder insights into Czech performance-based managed entry agreements: potential for transformative change in pharmaceutical access?","volume":"12","author":"Hospodkova","year":"2024","journal-title":"Healthc. (Basel)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1017\/S0266462307070651","article-title":"Coverage with evidence development: an examination of conceptual and policy issues","volume":"23","author":"Hutton","year":"2007","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/1472-6963-11-259","article-title":"Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts","volume":"11","author":"Jaroslawski","year":"","journal-title":"BMC Health Serv. Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2165\/11592960-000000000-00000","article-title":"Design of patient access schemes in the UK: influence of health technology assessment by the national institute for health and clinical excellence","volume":"9","author":"Jaroslawski","year":"","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1355203","DOI":"10.1080\/20016689.2017.1355203","article-title":"Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test","volume":"5","author":"Jorgensen","year":"2017","journal-title":"J. Mark. Access Health Policy"},{"key":"B55","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/1758-5899.12386","article-title":"Managing risk and uncertainty in health technology introduction: the role of managed entry agreements","volume":"8","author":"Kanavos","year":"2017","journal-title":"Glob. Policy"},{"key":"B56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1478-4505-11-31","article-title":"The financial burden from non-communicable diseases in low- and middle-income countries: a literature review","volume":"11","author":"Kankeu","year":"2013","journal-title":"Health Res. Policy Syst."},{"key":"B57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.18553\/jmcp.2020.26.1.63","article-title":"Examining misaligned incentives for payers and manufacturers in value-based pharmaceutical contracts","volume":"26","author":"Kannarkat","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1511679","DOI":"10.1080\/20016689.2018.1511679","article-title":"Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy","volume":"6","author":"Kefalas","year":"2018","journal-title":"J. Mark. Access Health Policy"},{"key":"B59","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/14737167.2017.1276828","article-title":"National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea","volume":"17","author":"Kim","year":"2017","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/14737167.2020.1758559","article-title":"The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways","volume":"21","author":"Kim","year":"2021","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"999220","DOI":"10.3389\/fphar.2023.999220","article-title":"Introduction of managed entry agreements in Korea: problem, policy, and politics","volume":"14","author":"Kim","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1017\/S0266462310001297","article-title":"What principles should govern the use of managed entry agreements?","volume":"27","author":"Klemp","year":"2011","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3402\/jmahp.v2.24988","article-title":"Health economic value of an innovation: delimiting the scope and framework of future market entry agreements","volume":"2","author":"Launois","year":"2014","journal-title":"J. Mark. Access Health Policy"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2015.61.2838","article-title":"Coverage with evidence development and managed entry in the funding of personalized medicine: practical and ethical challenges for oncology","volume":"33","author":"Lewis","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1377\/hlthaff.2019.00771","article-title":"Paying for value from costly medical technologies: a framework for applying value-based payment reforms","volume":"39","author":"Lopez","year":"2020","journal-title":"Health Aff. (Millwood)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13561-019-0242-x","article-title":"Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists","volume":"9","author":"Lorente","year":"2019","journal-title":"Health Econ. Rev."},{"key":"B67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40545-014-0019-x","article-title":"Patient access schemes in Asia-Pacific markets: current experience and future potential","volume":"8","author":"Lu","year":"2015","journal-title":"J. Pharm. Policy Pract."},{"key":"B68","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/11531510-000000000-00000","article-title":"We know accurately only when we know little","volume":"28","author":"MacLeod","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1002\/hec.3522","article-title":"Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success","volume":"27","author":"Mahjoub","year":"2018","journal-title":"Health Econ."},{"key":"B70","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jval.2018.11.016","article-title":"Conditional financing of drugs in the Netherlands: past, present, and future-results from stakeholder interviews","volume":"22","author":"Makady","year":"2019","journal-title":"Value Health"},{"key":"B71","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.vhri.2018.04.003","article-title":"Managed entry agreements for pharmaceutical products in Middle East and North African countries: Payer and manufacturer experience and outlook","volume":"16","author":"Maskineh","year":"2018","journal-title":"Value Health Reg. issues."},{"key":"B72","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/11530850-000000000-00000","article-title":"Access with evidence development schemes: a framework for description and evaluation","volume":"28","author":"McCabe","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"B73","doi-asserted-by":"publisher","first-page":"lsad014","DOI":"10.1093\/jlb\/lsad014","article-title":"Should Canada adopt managed access agreements in Canada for expensive drugs?","volume":"10","author":"McPhail","year":"2023","journal-title":"J. Law Biosci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/11530860-000000000-00000","article-title":"Principles of design of access with evidence development approaches: a consensus statement from the banff summit","volume":"28","author":"Menon","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"B75","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.hcmf.2011.02.008","article-title":"Access with evidence development: an approach to introducing promising new technologies into healthcare","volume":"24","author":"Menon","year":"2011","journal-title":"Healthc. Manage Forum"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e0281280","DOI":"10.1371\/journal.pone.0281280","article-title":"Association of exogenous factors with the access to innovative pharmaceutical products in Hungary","volume":"18","author":"Meresz","year":"2023","journal-title":"PLoS One"},{"key":"B77","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1750-1172-8-198","article-title":"Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries","volume":"8","author":"Morel","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1017\/S026646231900031X","article-title":"Improving access to high-cost technologies in the Asia region","volume":"35","author":"Mundy","year":"2019","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B79","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2014.09.007","article-title":"Do the current performance-based schemes in Italy really work? Success fee: a novel measure for cost-containment of drug expenditure","volume":"18","author":"Navarria","year":"2015","journal-title":"Value Health"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.18553\/jmcp.2017.23.10.1018","article-title":"Outcomes-based contracting experience: research findings from U.S. and European stakeholders","volume":"23","author":"Nazareth","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1377\/hlthaff.2010.1147","article-title":"Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement","volume":"30","author":"Neumann","year":"2011","journal-title":"Health Aff. (Millwood)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/1468-0009.12670","article-title":"Improving food and drug administration-centers for medicare and medicaid services coordination for drugs granted accelerated approval","volume":"101","author":"Neumann","year":"2023","journal-title":"Milbank Q."},{"key":"B83","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B84","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fphar.2017.00171","article-title":"Managed entry agreements for oncology drugs: lessons from the European experience to inform the future","volume":"8","author":"Pauwels","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000516501","article-title":"HTA reshaping: rethinking the health technology assessment framework in Portugal","volume":"39","author":"Pereira","year":"2021","journal-title":"Port. J. Public Health"},{"key":"B86","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/14737167.2023.2159813","article-title":"Medicaid best price reforms to enable innovative payment models for cell and gene therapies","volume":"23","author":"Quinn","year":"","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/14737167.2023.2193331","article-title":"Value-based performance arrangements for chronic conditions: an economic simulation of medicaid drug rebate program reforms","volume":"23","author":"Quinn","year":"","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1017\/S0266462317001106","article-title":"Characteristics of managed entry agreements in Australia","volume":"34","author":"Robinson","year":"2018","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B89","volume-title":"Top 10 most expensive prescription drugs in the US by price and by sales volume","author":"Rudy","year":"2025"},{"key":"B90","doi-asserted-by":"publisher","first-page":"31","DOI":"10.33393\/grhta.2022.2350","article-title":"How reliable are ICER's results published in current pharmacoeconomic literature? The controversial issue of price confidentiality","volume":"9","author":"Russo","year":"2022","journal-title":"Glob. Reg. Health Technol. Assess."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e007993","DOI":"10.1161\/CIRCOUTCOMES.121.007993","article-title":"Perks and pitfalls of performance-linked reimbursement for novel drugs: the case of Sacubitril-Valsartan","volume":"15","author":"Sandhu","year":"2022","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"B92","first-page":"1","article-title":"Outcomes-based pharmaceutical contracts","volume":"2017","author":"Seeley","year":"2017","journal-title":"An Answ. High U.S. Drug Spending? Issue Brief (Commonw Fund)"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1468-0262.t01-1-00268","article-title":"The mirrlees approach to mechanism design with renegotiation (with applications to Hold-up and risk sharing)","volume":"70","author":"Segal","year":"2002","journal-title":"Econometrica"},{"key":"B94","doi-asserted-by":"publisher","first-page":"771966","DOI":"10.3389\/fphar.2022.771966","article-title":"Critical reflections on reimbursement and access of advanced therapies","volume":"13","author":"Simoens","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13023-022-02397-4","article-title":"HTA decision-making for drugs for rare diseases: comparison of processes across countries","volume":"17","author":"Stafinski","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2147\/CEOR.S96616","article-title":"Targeting improved patient outcomes using innovative product listing agreements: a survey of Canadian and international key opinion leaders","volume":"8","author":"Thompson","year":"2016","journal-title":"Clin. Outcomes Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40258-016-0274-x","article-title":"The use of surrogate and patient-relevant endpoints in outcomes-based market access agreements: current debate","volume":"15","author":"Toumi","year":"2017","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.jval.2024.03.2196","article-title":"It takes 2 to tango. Setting out the conditions in which performance-based risk-sharing arrangements work for both parties","volume":"27","author":"Towse","year":"2024","journal-title":"Value Health"},{"key":"B99","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/11314080-000000000-00000","article-title":"Can't get no satisfaction? Will pay for performance help? toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products","volume":"28","author":"Towse","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"B100","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s41669-023-00460-9","article-title":"An analysis of uncertainties and data collection agreements in the cancer drugs fund","volume":"8","author":"Trigg","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"B101","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14737167.2019.1702525","article-title":"Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel","volume":"19","author":"Triki","year":"2019","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1017\/S0266462309990882","article-title":"Coverage with evidence development: applications and issues","volume":"26","author":"Trueman","year":"2010","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B103","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40273-018-0633-6","article-title":"The Australian managed entry scheme: are we getting it right?","volume":"36","author":"Tuffaha","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"B104","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jval.2011.12.013","article-title":"Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions","volume":"15","author":"Walker","year":"2012","journal-title":"Value Health"},{"key":"B105","volume-title":"Performance-based managed entry agreements for new medicines in OECD countries and EU member states: how they work and possible improvements going forward","author":"Wenzl","year":"2019"},{"key":"B106","volume-title":"A report into the uptake of patient access schemes in the NHS","author":"Williamson","year":"2009"},{"key":"B107","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2165\/11531160-000000000-00000","article-title":"Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa\/carbidopa (Duodopa(R)) in Sweden","volume":"8","author":"Willis","year":"2010","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B108","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jval.2012.02.004","article-title":"Australian managed entry scheme: a new manageable process for the reimbursement of new medicines?","volume":"15","author":"Wonder","year":"2012","journal-title":"Value Health"},{"key":"B109","doi-asserted-by":"publisher","first-page":"888404","DOI":"10.3389\/fmedt.2022.888404","article-title":"A proposal for value-based managed entry agreements in an environment of technological change and economic challenge for publicly funded healthcare systems","volume":"4","author":"Xoxi","year":"2022","journal-title":"Front. Med. Technol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.18553\/jmcp.2017.23.10.1084","article-title":"Paying for cures: how can we afford it? Managed care pharmacy stakeholder perceptions of policy options to address affordability of prescription drugs","volume":"23","author":"Yeung","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16020288","article-title":"Improving patient access to new drugs in South Korea: evaluation of the national drug formulary system","volume":"16","author":"Yoo","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B112","doi-asserted-by":"publisher","first-page":"106742","DOI":"10.1016\/j.phrs.2023.106742","article-title":"Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: a definite evidence from systematic review and meta-analysis on individual data","volume":"190","author":"Zinzi","year":"2023","journal-title":"Pharmacol. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1803870\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:24:22Z","timestamp":1776662662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1803870\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":112,"alternative-id":["10.3389\/fphar.2026.1803870"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1803870","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1803870"}}